Acute ischemic stroke
Conditions
Interventions
PT group:Randomly assigned to the PI group, patients were given 140mg (1ml) of ilozumab subcutaneously and 20mg of rosuvastatin calcium tablets orally within 1 hour. Starting from the next day, 20mg o
AT group:Randomly assigned to the AT group, patients were given 20mg of rosuvastatin calcium tablets orally within 1 hour, and 20mg of rosuvastatin calcium tablets orally once every night starting fro
Sponsors
First affiliated hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) 18 = Age = 80; 2) Patients with acute ischemic cerebrovascular disease within 24 hours of onset; 3) The history of atherosclerotic coronary heart disease was confirmed in the past; 4) Recurrent patients with first-time onset or previous cerebral infarction without sequelae such as limb paralysis will not affect the NIHSS score this time; Previous mRS score = 1 point; 5) Sign informed consent.
Exclusion criteria
Exclusion criteria: 1) Hemorrhagic stroke or mixed stroke 2) Patients with cerebral arteriovenous malformations or intracranial tumors 3) Uncontrollable severe hypertension (with systolic blood pressure still = 180mmHg or diastolic blood pressure = 110mmHg after active treatment), combined with severe infection (consistent with 1. body temperature = 38 ? 2. shock signs 3. consciousness disorders caused by infection 4. respiratory failure, blood gas analysis PO2100u/l or AST>80), renal dysfunction (glomerular filtration rate60 seconds, or INR>3) 4) Previous history of cerebral hemorrhage 5) Those who experience retinal or visceral bleeding within 30 days 6) Patients receiving PCSK9 inhibitors within 3 months prior to onset 7) Patients with consciousness disorders 8) Patients with previous allergies or intolerance to PCSK9 inhibitors or statin components 9) Pregnant or lactating women and those planning to conceive within 6 months Researchers believe that it is not suitable to participate in this experiment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of early neurological deterioration within 7 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| 30 day, 90 day mRS scores; Recurrence rate of symptomatic heart and brain events within 90 days;Changes in blood biochemical indicators (liver function, kidney function, blood lipids, etc.) before and after treatment at baseline, 7 days, 30 days, 90 days;Changes in inflammatory factors (IL-6, IL-8, TNF) before and after treatment- a), Baseline, 7 days; | — |
Countries
China
Contacts
Public ContactXiaofei Ji
First affiliated hospital of Dalian Medical University
Outcome results
None listed